文献速递冠心病心力衰竭与心肌病

短期阻断S100A9抑制促炎髓系细胞反应改善心肌梗死后心脏功能

Inhibition of pro-inflammatory myeloid cell responses by short-term S100A9 blockade improves cardiac function after myocardial infarction.
PubMed 文献 · Eur Heart J · 2019-01-01

该研究在524例急性冠脉综合征患者中发现,急性事件时高血浆S100A8/A9与1年时较低左心室射血分数及随访期间心衰住院增加相关。在小鼠心肌梗死模型中,炎症期给予S100A9阻断剂ABR-238901可抑制造血干细胞增殖及髓系细胞从骨髓排出,减少心肌中性粒细胞和单核/巨噬细胞数量,促进抗炎环境并显著改善心脏功能;在缺血/再灌注模型中,3天ABR-238901治疗使第21天左心室射血分数(48% vs. 35%,P=0.002)和心输出量(15.7 vs. 11.1 mL/min,P=0.002)显著改善。结论认为短期S100A9阻断可抑制炎症并改善小鼠心肌梗死后心脏功能,可能为改善ACS患者预后提供可行策略。

要点

  • ACS急性期高血浆S100A8/A9与1年左心室射血分数降低及心衰住院增加相关。
  • 小鼠MI炎症期短期阻断S100A9可减少心肌中性粒细胞和单核/巨噬细胞浸润。
  • 缺血/再灌注小鼠中3天ABR-238901治疗显著改善第21天左心室射血分数和心输出量。

核心结论

  • 短期S100A9阻断可抑制炎症并改善小鼠心肌梗死模型的心脏功能。
  • 鉴于S100A8/A9过度释放与心衰发生相关,S100A9阻断可能成为改善ACS患者预后的可行策略。

研究设计与样本

  • 研究纳入524例急性冠脉综合征患者,分析血浆S100A8/A9与1年左心室射血分数及随访期间心衰住院的关系。
  • 使用野生型C57BL/6小鼠行永久性冠状动脉结扎诱导心肌梗死,在炎症期给予S100A9阻断剂ABR-238901治疗。
  • 进一步在模拟临床情景的小鼠缺血/再灌注模型中验证ABR-238901(3天治疗)的效果。

主要发现

  • ACS患者急性事件时高血浆S100A8/A9与1年时较低左心室射血分数及随访期间心衰住院增加相关。
  • MI小鼠中ABR-238901治疗抑制造血干细胞增殖和髓系细胞从骨髓排出,减少心肌中性粒细胞和单核/巨噬细胞数量,促进抗炎环境。
  • 与MI对照相比,ABR-238901治疗显著改善心脏功能。
  • 缺血/再灌注小鼠中,与未治疗组相比,3天ABR-238901治疗使第21天左心室射血分数显著改善(48% vs. 35%,P=0.002),心输出量显著改善(15.7 vs. 11.1 mL/min,P=0.002)。

临床怎么用

  • ACS急性期血浆S100A8/A9水平可能有助于识别1年左心室射血分数降低及心衰住院风险较高的患者。
  • 短期S100A9阻断作为改善心肌梗死后心脏功能的潜在策略,目前证据仅来自小鼠模型,尚需临床研究验证。

局限性

  • S100A9阻断改善心脏功能的证据来自小鼠心肌梗死及缺血/再灌注模型,尚未在患者中验证。
  • ACS患者部分为观察性关联分析,未报告S100A8/A9阻断在人群中的干预效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Neutrophils have both detrimental and beneficial effects in myocardial infarction (MI), but little is known about the underlying pathways. S100A8/A9 is a pro-inflammatory alarmin abundantly expressed in neutrophils that is rapidly released in the myocardium and circulation after myocardial ischaemia. We investigated the role of S100A8/A9 in the innate immune response to MI. METHODS AND RESULTS: In 524 patients with acute coronary syndrome (ACS), we found that high plasma S100A8/A9 at the time of the acute event was associated with lower left ventricular ejection fraction (EF) at 1-year and increased hospitalization for heart failure (HF) during follow-up. In wild-type C57BL/6 mice with MI induced by permanent coronary artery ligation, treatment with the S100A9 blocker ABR-238901 during the inflammatory phase of the immune response inhibited haematopoietic stem cell proliferation and myeloid cell egression from the bone marrow. The treatment reduced the numbers of neutrophils and monocytes/macrophages in the myocardium, promoted an anti-inflammatory environment, and significantly improved cardiac function compared with MI controls. To mimic the clinical scenario, we further confirmed the effects of the treatment in a mouse model of ischaemia/reperfusion. Compared with untreated mice, 3-day ABR-238901 treatment significantly improved left ventricular EF (48% vs. 35%, P = 0.002) and cardiac output (15.7 vs. 11.1 mL/min, P = 0.002) by Day 21 post-MI. CONCLUSION: Short-term S100A9 blockade inhibits inflammation and improves cardiac function in murine models of MI. As an excessive S100A8/A9 release is linked to incident HF, S100A9 blockade might represent a feasible strategy to improve prognosis in ACS patients.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Marinković G, Grauen Larsen H, Yndigegn T, et al. Inhibition of pro-inflammatory myeloid cell responses by short-term S100A9 blockade improves cardiac function after myocardial infarction. Eur Heart J. 2019. PMID: 31292614. doi:10.1093/eurheartj/ehz461

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。